These findings leverage natural resilience to illuminate posttranscriptional regulation in human HSCs, suggesting that inhibition of MSI2 or its targets could be rational strategies for blood cancer prevention. Here, MSI2 is linked to hematopoietic and lymphoid system neoplasm.